Abiraterone and Docetaxel Treatments Increase Phospho-PTEN Expression in Metastatic Prostate Cancer Cells

Aim: Prostate cancer is the second leading cause of death in cancer-related deaths men. Docetaxel and abiraterone acetate are widely used treatment castration-resistant metastatic prostate cancer. Phospho-PTEN triggers proliferation, migration, angiogenesis survival cells by causing oncogenic Akt hyperactivation. This study, it aimed to investigate effects docetaxel agents, which cancer, on expression phospho-PTEN, stimulates pathway. Material Methods: The phospho-PTEN androgen receptor (+) (-) cell lines were investigated vitro immunofluorescence method. Results: Findings compatible both lines. No statistically significant difference was observed between control groups. increased acetate+docetaxel groups compared control. increase greater combined group given two agents group. Conclusion: A causes According this information, drug treatments may support pathway increasing patients. To eliminate these patients, administration that dephosphorylate PTEN or will stimulate pathways provide dephosphorylation total